Premium
Trends in meningococcal disease: challenges for vaccine control when disease is rare
Author(s) -
Pollard Andrew J,
Christensen Hannah
Publication year - 2017
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja17.00514
Subject(s) - meningococcal disease , disease , medicine , rare disease , disease control , meningococcal vaccine , virology , neisseria meningitidis , immunology , biology , immunization , immune system , genetics , bacteria
The clinical, social and economic value of vaccination varies both with time and by population group In most wealthy and in many middle income countries, capsular group B Neisseria meningitidis (MenB) remains an important cause of invasive disease, particularly in the era of control of other major bacterial pathogens, such as MenC, Haemophilus influenzae type b, and vaccine-type pneumococcus. Two new MenB vaccines (now licensed in many countries) provide the potential for a comprehensive approach to controlling these invasive bacterial pathogens. However, decisions about vaccination at the population level are complex when there are low rates of disease: cost-effectiveness is a particularly important factor